GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medtide 3880.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

19.33

-2.47%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Medtide

Its shares trade on HKEX under the ticker 3880.HK. It has been listed since 30 June 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥570.1m and net income of CN¥217.4m. At that date it held total assets of CN¥1.81bn and shareholders' equity of CN¥1.58bn.

Medtide, Inc. is a peptide focused contract research, development and manufacturing organization. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2025-06-30. The firm mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The firm's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The firm also provides customers with peptide drug development, production, and CMC filing support services. The firm mainly operates its business in the domestic market and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
30 Jun 2025
Employees
522

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Peptide-focused CRO and CDMO services with expertise in NCE discovery synthesis
  • Provides comprehensive API development and manufacturing services including CMC
  • Operates in both domestic and overseas markets with 522 employees

Weaknesses

  • IPO scheduled for 2025-06-30, indicating limited historical market presence
  • Relies on domestic market operations with unclear international market share
  • Services primarily focus on APIs rather than drug products, limiting scope

Opportunities

  • Growing demand for peptide-based pharmaceuticals in global markets
  • Potential to expand overseas market presence beyond current operations
  • Increasing need for CRO/CDMO services in life sciences sector

Threats

  • IPO in 2025-06-30 may face market volatility during listing
  • Competition from established CRO/CDMO providers in life sciences
  • Dependence on peptide-focused services may limit adaptability to market changes

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.